---ADDS QUOTES FROM COMPANY, SHARE PRICE---
ValiRx (LON:VAL) said its agreed an expanded and adaptive protocol for its first-in-man studies on VAL 201, its drug candidate being developed for prostate cancer.
“We have got the point now where now know how and what we are going to put into human beings and what we are trialling in detail,” said ValiRx chief operations officer George Morris.
“So we know what the trial will look like, what we aim to get from it and have a fairly good idea of most of the ancillary detail.”
The first-in-man trial, which assess tolerability and safety of the treatment as well as early signs of efficacy, will reveal its results as planned by the end of the year.
In the same announcement it was revealed the Institut Paoli-Calmettes, in France, has provisionally agreed to conduct further efficacy studies and undertake clinical studies on VAL201 in additional cancer indications.
“We now have a second site for later on in the trailing process when we can’t do it for just one centre,” said Morris.
Meanwhile, the European Medicines Agency has said ValiRx is eligible for the administrative and financial assistance afforded small and medium-sized firms.
The shares, up 13% in the last six months, eased 2% in afternoon trade to 0.44 pence.
